AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03091842 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03091842 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03091842 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03588195 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Program
Description: Educational program consist in 5 consecutive sessions held once a week, with a duration of 60 minutes each class and at the end of the last class, a booklet was delivered for each patient with all the contents of the classes. This group also received Transcutaneous Nerve Electro-Stimulation twice weekly, for 5 weeks for 40 minutes each session
Study NCT03588195 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Nerve Electro-Stimulation
Description: Transcutaneous Nerve Electro-Stimulation performed twice weekly, for 5 weeks for 40 minutes each session
Study NCT03588195 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Nerve Electro-Stimulation
Description: Transcutaneous Nerve Electro-Stimulation performed twice weekly, for 5 weeks for 40 minutes each session
Study NCT03615404 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CMV-DCs with GM-CSF
Description: CMV-DCs are autologous dendritic cells derived from PBMCs loaded with RNA encoding the human CMV matrix protein pp65 as a fusion protein with the full-length LAMP protein (pp65-flLAMP) plus GM-CSF.
Study NCT03615404 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Td (tetanus toxoid)
Description: Patients will receive preconditioning with Td in the right groin, and approximately 6-24 hours later, they will receive their first CMV-DC vaccination. Patients will also receive Td preconditioning approximately 6-24 hours prior to their 4th vaccine and subsequent vaccines, if any.
Study NCT03536767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG10
Description: AG10 800mg twice daily, oral administration
Study NCT04008004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-514
Description: Oral Capsule; Subjects will receive either a single dose of EDP-514 on Day 1 only (SAD HV), once daily dosing of EDP-514 starting on Day 1 through Day 14 (MAD HV) or once daily dosing of EDP-514 starting on Day 1 through Day 28 (MAD HBV).
Study NCT04008004 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match EDP-514
Study NCT04526262 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial magnetic resonance guided focused ultrasound BBB disruption
Description: The ExAblate BBB disruption procedure will be performed with ExAblate 4000 type 2.0 system, and this will be performed twice every 3 months.
Study NCT01150942 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: JE vaccine
Description: 3 times, IM
Study NCT01150942 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JE vaccine
Description: 3 times, IM
Study NCT01461187 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise during pregnancy
Description: supervised aerobic physical exercises twice a week.
Study NCT03584412 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT OPEN
Description: Participants will access the ACT OPEN treatment through a secure online platform. Each session consists of brief videos and audio recordings that provide information about pain and guide participants through experiential exercises (e.g., mindfulness, values clarification, goal-setting). Participants will respond to questions assessing their experiences during the session and their progress using online messaging and/or brief telephone calls according to their preference. Therapists will provide individualised feedback. ACT OPEN consists of 12 sessions over 6 weeks. Participants will be given two further weeks to finish any uncompleted sessions, or to complete additional sessions (up to four) as agreed with their therapist.
Study NCT02234921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: A single dose of cyclophosphamide, 300 mg/m2, will be administered intravenously 3 Days prior to the first vaccine.
Study NCT02234921 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DRibble Vaccine
Description: DRibble vaccine will be administered at Weeks 1, 4, 7, 10, 13, 16, 19 and 22. Eight vaccinations will be administered. Week 1 and 4 vaccines will be administered by intranodal injections performed using ultrasound guidance.
Study NCT02234921 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV Vaccinations
Description: Patients will receive a dose of 0.5-mL CERVARIX at week 1 (Day 4) and week 7 by intramuscular injection at a site distant from the DRibble vaccine.
Study NCT02234921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: Imiquimod cream (5%, 250 mg) will be self-applied topically for 5 consecutive days by patients to a 4 x 5-cm outlined area of healthy extremity skin starting on the day of the second vaccine and again during each additional vaccine cycle.
Study NCT03984786 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assessment Interview
Description: An interviewer will administer a pre-treatment assessment interview. This 30-45 minute interview will be performed after randomization immediately after the initial telephone screen, where the interviewer will use the AUD section of the SCID-5.
Study NCT03984786 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guidance
Description: Guidance from a health educator through regular weekly online messages. Participants may also be contacted through emails and phone calls. The team of guides consists of registered social workers, psychologists, and graduate students, with experience delivering ICBT.
Study NCT03984786 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ICBT for alcohol misuse
Description: The 8-week internet-delivered cognitive behaviour therapy (ICBT) course for alcohol misuse. The course consists of 12 lessons distributed across 8 weeks (1 to 2 lessons a week).
Study NCT03584412 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Waiting list control
Description: Participants will receive their usual treatment for 5 months, after which they will complete ACT OPEN as described. A waiting list control was chosen as there is no clearly credible active psychotherapy to serve as the comparator in this context, particularly in light of high drop-out rates in two previous studies of CBT for pain in HIV. Providing the online treatment without therapist support may appear to be a logical comparison group instead of a waitlist control. However, there is evidence that therapist support is a key component of online CBT and, therefore, without this support it may not represent a credible treatment against which to judge the full treatment. In the context of the feasibility aims of this trial these reasons, the use of a waiting list control is thus justified.
Study NCT03039959 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: No intervention
Description: No intervention
Study NCT03266601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Interferon α-2b Spray
Description: Recombinant human interferon α-2b spray (trade name Jeferon, specifications: 1 million U/support, 10mL/support or 2 million U/support, 20mL/support, 2-8 ℃ dark storage and transportation), 1 million U/day, used for 3 days, observed to the 4th day (until the 96th hour).
Study NCT03266601 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: Ribavirin Spray, spray once every 4-5 hours, 1-2 times a spray, used for 3 days, observed to the 4th day(until the 96th hour ).
Study NCT01190631 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acrysof IQ (SN60WF) IOL
Description: Acrysof IQ (SN60WF) intraocular lens implanted in the capsular bag of the eye during cataract surgery. The IOL is intended for the lifetime of the patient. Unilateral (one eye only) implantation is planned.
Study NCT04419753 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: attention focus walking training
Description: Use different attention focus instructions or no attention focus instruction during walking training in older adults to examine whether the attention focus instructions can ameliorate conscious motor processing and optimize rehabilitation outcome measurements.
Study NCT04419753 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: attention focus walking training
Description: Use different attention focus instructions or no attention focus instruction during walking training in older adults to examine whether the attention focus instructions can ameliorate conscious motor processing and optimize rehabilitation outcome measurements.
Study NCT02152605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UMEC/VI
Description: Dry white powder delivered via DPI (2 strips with 30 blisters each, first containing UMEC 62.5 mcg per blister and second containing VI 25 mcg per blister), administered as one inhalation of UMEC/VI 62.5/25 mcg
Study NCT02621814 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low glycation formula feeding
Description: Formula feeding on demand for 3 months
Study NCT02621814 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Commercially common formula feeding
Description: Formula feeding on demand for 3 months
Study NCT02374879 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood Glucose Monitoring Systems.
Description: In vitro diagnostic medical device.
Study NCT00181961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maca Root
Study NCT02665416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selicrelumab
Description: Selicrelumab will be provided as concentrate for solution to be administered via SC injection
Study NCT02665416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vanucizumab
Description: Vanucizumab will be provided as solution to be administered via IV infusion.
Study NCT02665416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered via IV infusion.
Study NCT02152605 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dry white powder delivered via DPI (2 strips with 30 blisters each, both containing lactose with magnesium stearate), administered as one inhalation of placebo
Study NCT01373138 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desloratadine and pseudoephedrine
Description: Desloratadine and pseudoephedrine 5/240 mg
Study NCT04019925 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ADM/MDM hip
Description: Dual Mobility Hip prosthesis manufactured by Stryker Orthopaedics: ADM/MDM
Study NCT00982800 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: 200mg 3x/day for 3 days (9 doses total)
Study NCT00982800 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Sugar Pill
Study NCT03229512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Topical 1% Sildenafil Cream
Study NCT01373138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desloratadine and pseudoephedrine
Description: Desloratadine and pseudoephedrine 5/240 mg
Study NCT02864992 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tepotinib
Description: Subjects will receive 500 milligram (mg) of tepotinib once daily in cycles of 21-day duration until disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent.
Study NCT05652114 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mightier
Description: Mightier is an app-based biofeedback video game that utilizes heart rate (HR) monitoring during game play to teach and facilitate practice of emotional regulation skills in children.
Study NCT01654198 — intervention group
Intervention type: RADIATION
Intervention: FDG-PET/CT scan
Description: FDG-PET/CT is a type of imaging used currently to look for cancer. We are using it to look at inflammation within the joints.
Study NCT00634998 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: 1000mg Vitamin C capsules orally twice daily
Study NCT00634998 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1000mg Placebo capsules orally twice daily for 90 days
Study NCT03019289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pridopidine (90 mg)
Description: single dose will be administered in Cohort 1. Other optional cohorts 2 and 3 may include single dose 0.5 mg, 1 mg, 2.5 mg, 5 mg, 10 mg, 22.5 mg, 45 mg, or 90 mg. The dose will be selected based on the results obtained from Cohorts 1 and 2.
Study NCT00537914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omnitrope
Description: All enrolled patients received Omnitrope. The median daily dose varied between 0.0340 and 0.0351 mg/kg/day and the maximum range was 0.000 to 0.040 mg/kg/day over all visits.
Study NCT00025376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PS-341
Study NCT00025376 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor Biopsy
Study NCT04053491 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hand surgery under regional anesthesia
Description: In both groups, patients will benefit from an initial standardized bolus (long-acting local anesthetic, ropivacaine) to cover the operative period, via the allocated approach. Ultrasound guidance and the recommended standards monitors will be used in both groups. After the initial bolus, a catheter will be inserted via the allocated approach. Surgery will be done under regional anesthesia alone, unless there is a medical contraindication or if the patient asks for general anesthesia. Post-operative analgesia will be standardized with regular paracetamol, regular NSAID (Nonsteroidal anti-inflammatory drugs) and oxycodone if needed. The local anesthetics perfusion will be standardized. There will be a medical follow up at 24 and 48 hours where data will be collected.
Study NCT01654315 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Myomo Robotic Arm
Description: Patients are administered rehabilitative therapy (repetitive task specific therapy,, also known as RTP' in this study) using only the Myomo robotic device targeting their affected arms on 3 days/week during a 8 week period. These patients engage in RTP, which consists of a battery of activities that emphasize use of their affected arms repetitively, with the device providing assistance as needed with movement through the arm's range of motion.
Study NCT01654315 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: RTP Standard Therapy
Description: Active Comparator: RTP Group Patients are administered rehabilitative therapy using only RTP that is targeting their affected arms on 3 days/week during a 8 week period. In this condition, patients engage in activities that emphasize use of their affected arms repetitively, with the therapist providing assistance as needed with movement through the arm's range of motion. As patients progress, the amount of assistance provided by the therapist during the activities is reduced.
Study NCT03209895 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Joint Health Product
Description: Krill oil, Astaxanthin, Hyaluronic Acid Formulation, 353 mg per day; Softgel capsule
Study NCT03209895 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Palm oil Softgel capsule
Study NCT03209895 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glucosamine / Chondroitin
Description: Glucosamine 1500 mg, Chondroitin 1200 mg per day
Study NCT04343131 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary intervention
Description: Crossover dietary manipulation using three different types of diet for 7 days each
Study NCT00115453 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: irradiation
Description: Boronophenylalanine is infused into a peripheral vein prior to neutron irradiation.
Study NCT03570801 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Expert Panel Review
Description: There is some preliminary evidence suggesting that having a group of spinal experts review x-rays prior to treatment might provide useful information to the patient and the patients' treating physician when trying to make a decision about what type of surgery to perform.
Study NCT02684149 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: relational touch
Study NCT02435732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo saline solution
Description: saline solution
Study NCT02435732 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo saline solution
Description: saline solution
Study NCT01669083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK557296 10 mg
Description: 10 mg single oral dose. Each subject will receive 2 tablets of 5 mg GSK557296 four times a day (QID).
Study NCT01669083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK557296 150 mg
Description: 150 mg single oral dose. Each subject will receive multiple tablets of 25 mg GSK557296 either 2, 3 or 4 times a day.
Study NCT01669083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK557296 dose 3
Description: Dose to be determined as a single dose tablet based on half-life demonstrated in Cohort 1 and Cohort 2.
Study NCT01669083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK557296 dose 4
Description: Dose to be determined by PK of prior doses, based on half-life demonstrated in prior cohorts.
Study NCT02413489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab 16 mg/kg will be administered as intravenous infusion to participants once every week for 8 weeks; then once every other week for 16 weeks; thereafter once every 4 weeks until documented progression, unacceptable toxicity, or study end.
Study NCT00313612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV
Study NCT00313612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan
Description: Given IV
Study NCT01623596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod
Study NCT01623596 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Disease Modifying therapy
Study NCT02435732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Description: Added to the one of the arms receiving 200U/kg dose of CINRYZE
Study NCT02435732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CINRYZE
Description: 200U/kg IV dose with or without heparin, or 500U/kg IV dose
Study NCT00489216 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: efalizumab
Description: Efalizumab will be administered as a subcutaneous injection once a week for 8 weeks (total of 8 doses). First efalizumab injection will be dosed at 0.7mg/kg. Subsequent weekly injections given on days 8-50 will be dosed at~1mg/kg
Study NCT00298727 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SHIPS
Description: Stakeholder-Hosted Interactive Problem-based Seminars
Study NCT00298727 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ePBL
Description: Online Problem-Based Course
Study NCT00587860 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: St. John's wort
Description: Dosage form: Tablet (450 mg) Dose: 450 mg twice a day, placebo twice a day
Study NCT00587860 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosage form: Tablet (450 mg) Dose: 450 mg twice a day, placebo twice a day
Study NCT03953794 — intervention group
Intervention type: DEVICE
Intervention: Fitbit Charge 3
Description: Smart watch monitoring activity and movement, heart rate, sleep, and more
Study NCT00160147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bifeprunox
Description: One week titration with dose adjustments
Study NCT01627678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vacc-C5/GM-CSF
Description: Arm 1=Arm A: Vacc-C5 with GM-CSF as adjuvant administered intradermally.
Study NCT01627678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vacc-C5/Alhydrogel
Description: Arm 2=Arm B: Vacc-C5 with Alhydrogel as adjuvant administered intramuscularly.
Study NCT00160147 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06040021 — intervention group
Intervention type: OTHER
Intervention: standardized treatment
Description: Patients enrolled in these 2 cohorts all received standardized treatment of colorectal cancer.
Study NCT05952388 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Behavioral Patient care
Description: chart review
Study NCT04346446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Convalescent Plasma Transfusion
Description: Convalescent Plasma Transfusion
Study NCT04346446 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive Care
Description: Supportive Care
Study NCT04346446 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Care
Description: Supportive Care
Study NCT04346446 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Random Donor Plasma
Description: Random Donor Plasma will be transfuse from 200 to 600 mL according to the patient requirement